Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 3/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992736 | 1.00 | RORC (0.52) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL19459065 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL19490839 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL19458917 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL24495119 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL24495116 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL19458918 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL16799262 | 0.88 | RORC (0.49) | RORCPDE4BUSP30FPR2FPR3 | |
| SCHEMBL17514225 | 0.86 | RORC (0.52) | RORCPDE4BUSP30NAMPTKCNK3 | |
| SCHEMBL20148981 | 0.86 | RORC (0.68) | RORCPDE4BUSP30FPR2FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619406-A1 | TRICYCLIC COMPOUNDS | Schrödinger, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | RORC 887/4885PDE4B 1008/4885USP30 3863/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | RORC 887/4885PDE4B 1008/4885USP30 3863/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | RORC 887/4885PDE4B 1008/4885USP30 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.